Development of second-generation amphotericin B molecular prosthetics for enhanced therapeutic efficacy in cystic fibrosis
Marin-Toledo, Johnnathan P
This item's files can only be accessed by the System Administrators group.
Permalink
https://hdl.handle.net/2142/127475
Description
Title
Development of second-generation amphotericin B molecular prosthetics for enhanced therapeutic efficacy in cystic fibrosis
Author(s)
Marin-Toledo, Johnnathan P
Issue Date
2024-12-04
Director of Research (if dissertation) or Advisor (if thesis)
Burke, Martin D
Doctoral Committee Chair(s)
Burke, Martin D
Committee Member(s)
Hergenrother, Paul
Mehta, Angad
Grosman, Claudio
Department of Study
Chemistry
Discipline
Chemistry
Degree Granting Institution
University of Illinois at Urbana-Champaign
Degree Name
Ph.D.
Degree Level
Dissertation
Keyword(s)
Amphotericin B
Cystic Fibrosis
Cftr
Anion-selective
Language
eng
Abstract
Using small molecules, molecular prosthetics (MPs) to replace the function of missing or dysfunctional proteins as a therapeutic strategy to treat genetic disorders has made great strides over the years. In particular, for channelopathies, Amphotericin B (AmB), an ion channel-forming small molecule, has shown promise and surprising versatility as an MP by effectively replacing potassium-selective ion channels in yeast and bicarbonate-selective ion channels in human airway epithelial models. Despite its cation-permeable nature, AmB remains somewhat permeable to anions, although not to a high degree, which allows for this versatility. However, in this thesis, we explore the limitations of this versatility and develop strategies to overcome them to generate a next generation of AmB-based MPs that better replace individual ion channels. A series of AmB derivatives were rationally designed and synthetically prepared to study the ion selectivity, conductance, and toxic properties of the next generation of MPs using new electrophysiological and pre-clinical therapeutic models. These studies led to the discovery of the anion-selective MP, AmB-AA, which demonstrated superior performance compared to AmB and reduced the homeostatic burden that a cation-permeable molecule like AmB was causing in CF models. Additionally, these derivatives helped highlight key properties of the AmB ion channels, providing insight into the mechanism that enabled the development of a next generation AmB-based, epithelial-sparing, anion-selective molecular prosthetic, C2’epiAmB-AA, for the treatment of Cystic Fibrosis (CF).
Use this login method if you
don't
have an
@illinois.edu
email address.
(Oops, I do have one)
IDEALS migrated to a new platform on June 23, 2022. If you created
your account prior to this date, you will have to reset your password
using the forgot-password link below.